Insider Trading Activity Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – CEO Bought 47,058 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Douglas S Ingram , CEO of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reportedly Bought 47,058 shares of the company’s stock at an average price of 42.5 for a total transaction amount of $1,999,965.00 SEC Form

Insider Trading History For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

On 9/7/2012 M Kathleen Behrens, Director, bought 17,500 with an average share price of $14.73 per share and the total transaction amounting to $257,775.00.View SEC Filing

On 6/14/2013 Anthony R Chase, Director, bought 10,000 with an average share price of $38.50 per share and the total transaction amounting to $385,000.00.View SEC Filing

On 8/20/2013 Sandesh Mahatme, CFO, bought 5,000 with an average share price of $31.10 per share and the total transaction amounting to $155,500.00.View SEC Filing

On 8/22/2013 Anthony Chase, Director, bought 3,500 with an average share price of $32.68 per share and the total transaction amounting to $114,380.00.View SEC Filing

On 9/3/2013 John Hodgman, Director, sold 5,556 with an average share price of $34.97 per share and the total transaction amounting to $194,293.32.View SEC Filing

On 9/16/2013 M Kathleen Behrens, Director, bought 6,500 with an average share price of $37.04 per share and the total transaction amounting to $240,760.00.View SEC Filing

On 11/14/2013 Anthony Chase, Director, bought 10,000 with an average share price of $13.95 per share and the total transaction amounting to $139,500.00.View SEC Filing

Analyst Ratings For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
These are 4 Hold Ratings, 15 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is Buy (Score: 2.85) with a consensus target price of $62.50 , a potential (53.15% upside)

Analyst Ratings History For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

On 9/1/2015 Susquehanna Bancshares Inc Boost Price Target of rating Neutral with a price target of $33.00 to $36.00
On 10/23/2015 Bank of America Corporation Initiated Coverage of rating Buy with a price target of $49.00
On 11/8/2015 Roth Capital Reiterated Rating Buy with a price target of $50.00
On 5/5/2016 Ladenburg Thalmann Financial Services Downgraded rating Market Perform to Underperform with a price target of $13.00 to $5.00
On 9/20/2016 WBB Securities Reiterated Rating Strong-Buy with a price target of $40.00 to $60.00
On 10/27/2016 Wedbush Reiterated Rating Outperform with a price target of $72.00
On 12/20/2016 Goldman Sachs Group, Inc. (The) Initiated Coverage of rating Neutral with a price target of $40.00

Recent Trading Activity for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Shares of Sarepta Therapeutics, Inc. closed the previous trading session at 40.81 up +0.23 0.57% with 4,134,949 shares trading hands.